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1606Background: A new oro-dispersible film (ODF) formulation of sildenafil has been developed for the treatment
of erectile dysfunction (ED) to overcome the drawbacks that some patients experience when taking the con-
ventional film-coated tablet (FCT).
Aim: To assess the effectiveness and safety of sildenafil ODF formulation in patients with ED who were using
the conventional FCT.
Methods: From May 2017 through July 2017, 139 patients with ED were enrolled. Data from penile color-
duplex ultrasound, medical history, hormonal evaluation, and patient self-administered questionnaires were
collected. All patients were administered sildenafil 100-mg FCT for 4 weeks. Thereafter, they underwent a
2-week washout period and subsequently took sildenafil 75-mg ODF for 4 weeks.
Outcomes: The International Index of Erectile Function (IIEF-15), Hospital Anxiety and Depression Scale
(HADS), Patient Global Impressions of Improvement (PGI-I), and Clinician Global Impressions of Improve-
ment (CGI-I) questionnaires were administered and severity of ED was classified as severe (IIEF-15 score  10),
moderate (IIEF-15 score 11e16), or mild (IIEF-15 score ¼ 17e25).
Results: All patients completed the final protocol. Differences in mean IIEF scores for erectile function,
orgasmic function, sexual desire, and intercourse satisfaction were significantly in favor of sildenafil 100-mg FCT,
whereas the mean score for overall satisfaction was in favor of sildenafil 75-mg ODF. A significant difference in
changes in HADS score was found from washout to final follow-up (mean difference ¼ 0.19; P < .01). For the
ODF formulation, the median CGI-I score was 3.5 (interquartile range [IQR] ¼ 2.5e4.5) and the median PGI-I
score was 3.0 (IQR ¼ 2.0e4.0). The median action time was 20.0 minutes (IQR ¼ 15.0e30.0) and the median
mouth time was 60.0 seconds (IQR ¼ 30.0e120.0).
Clinical Implications: The ODF formulation of a widely known drug, with the same safety and effectiveness of
the FCT, was better appreciated by patients in overall satisfaction.
Strengths and Limitations: This is the first clinical trial to assess the efficacy of a new formulation of sildenafil
in patients with ED. The limitations of the study are related to the methodology used: it was not a case-control
study and the patients were not drug-naïve for ED treatment. Therefore, only the “additional” side effects of the
ODF formulation compared with FCT are reported.ly 31, 2017. Accepted October 24, 2017.
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Efficacy of a New Sildenafil Oral Formulation 1607Conclusion: The new ODF formulation is as efficient and safe as the FCT formulation and offers a new choice
of treatment to specialists for more precisely tailored therapy. Cocci A, Capece M, Cito G, et al. Effectiveness
and Safety of Oro-Dispersible Sildenafil in a New Film Formulation for the Treatment of Erectile
Dysfunction: Comparison Between Sildenafil 100-mg Film-Coated Tablet and 75-mg Oro-Dispersible
Film. J Sex Med 2017;14:1606e1611.
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Erectile dysfunction (ED) is defined as the inability to obtain
or maintain an erection sufficiently rigid for achieving satisfactory
sexual performance.1 It affects nearly 50% of men older than 40
years, causing patients serious distress and prompting them to
seek medical opinions they might not otherwise seek.2
ED has a significant impact on the quality of life of patients
because it influences the self-perception and sexuality of those
men and might undermine their interactions with women or
potential partners.3 Because sexual satisfaction is considered a
major predictor of life satisfaction, treatment of ED would likely
improve the quality of life for these patients and their partners.4
Many therapeutic options are available for the treatment of
ED. One option is the use of phosphodiesterase type 5 inhibitors
(PDE5is). PDE5is, including sildenafil, tadalafil, vardenafil, and
avanafil, are currently approved for use in ED and each has an
individual pharmacokinetic and side effects profile, although no
significant differences in efficacy among therapies are
evident.1,5e8
Sildenafil, the first approved PDE5i, is a safe and effective oral
agent for the treatment of ED and is predominantly metabolized
by cytochrome P-450 into an N-desmethyl metabolite (N-
desmethyl sildenafil) that accounts for approximately 1 fifth of
the drug’s activity.9,10
Oral administration of a tablet can lead to 2 types of effects.
(i) The original formulation is inconvenient for patients because
water is required for the medicine to be taken. (ii) Oral
administration of the tablet relies on the patient’s ability to
swallow the dosage safely, which could be problematic for in-
dividuals who have swallowing disorders. Dysphagia has an
estimated of 22% in patients older than 50 years.11 To overcome
these drawbacks, a new oro-dispersible film (ODF) formulation
was developed. It is quickly dispersed in the mouth and can be
administered without water.12
According to the Biopharmaceutics Classification System,
sildenafil is classified as a class II drug substance (high perme-
ability and low solubility). The new sildenafil ODF formulation,
developed by IBSA (Lugano, Switzerland), is approved in Europe
at doses of 25, 50, 75, and 100 mg. Each sildenafil 75-mg ODF
contains sildenafil citrate 105.3 mg, equivalent to sildenafil 75
mg, in the form of a rectangular, flexible, opaque, light-blue film
measuring 40  45 mm, whereas each sildenafil 100-mg2017;14:1606e1611film-coated tablet (FCT) contains sildenafil citrate 140.4 mg,
equivalent to sildenafil 100 mg. A previous study compared the 2
treatments with the same active substance but with different
dosages and different formulations. It was a non-inferiority study
of the 2 treatments for effectiveness, not for bioequivalence.13
The ODF formulation is an innovative patented product
developed in accordance with EP 1689374 (self-supporting films
for pharmaceutical and food use) and WO 2014/049548 (ODFs
with quick dissolution times for therapeutic and food use).13
We evaluated the efficacy and safety of the sildenafil ODF
formulation in patients with ED who were taking the conven-
tional sildenafil FCT.
METHODS
From May 2017 through July 2017, we enrolled 139 patients
with a history of chronic ED. The etiology of ED was deter-
mined, in all cases, by a standard protocol involving penile color-
duplex ultrasound, complete medical history, hormonal evalua-
tion, and patient self-administered questionnaires on sexual
function. We measured serum concentrations of
follicle-stimulating hormone (normal range ¼ 1.5e8.0 IU/L),
prolactin (3.0e18 ng/mL), thyroid-stimulating hormone
(0.3e5.5 mIU/L), luteinizing hormone (1.8e12 IU/L), and
total testosterone (2.7e18 ng/mL).
Inclusion criteria were heterosexual men younger than 75
years, presence of ED evaluated through the International Index
of Erectile Function (IIEF), sexual intercourse at least 2 times per
week, an Eastern Cooperative Oncology Group (ECOG) scale of
performance status score no higher than 1, absence of moderate
or severe cardiovascular diseases, and moderate ED according to
penile dynamic Doppler examination. All patients enrolled in the
study were eligible for first-line therapy of ED based on PDE5i,
according to European Association of Urology, American Uro-
logical Association, and International Society for Sexual Medi-
cine guidelines. Exclusion criteria were being unable or unwilling
to provide informed consent, an IIEF score lower than 16,
presence of unstable coronary artery disease (ECOG score > 1),
sexual intercourse no more than 1 time per week, concomitant
use of nitrates in any form, and known hypersensitivity to sil-
denafil or its components. Men with ED based on neurogenic,
hormonal, or anatomic conditions and those who underwent
previous surgical treatment of the penis or pelvic area were
excluded from the study.
Table 1. Baseline characteristics of the population (N ¼ 139)
Variables
Age (y), median (IQR) 66.6 (63.3e69.0)
BMI (kg/m2), median (IQR) 14.0 (12.0e16.0)
IIEF domain scores, median (IQR)
Erectile function 14.0 (12.0e17.0)
Orgasmic function 3.0 (2.0e5.0)
Sexual desire 3.0 (2.0e3.0)
Intercourse satisfaction 4.0 (3.0e6.0)
Overall satisfaction 6.0 (4.0e7.0)
Classification of ED, n (%)
Severe 19 (13.7)
Moderate 65 (46.8)
Mild 55 (39.6)
HADS score, median (IQR) 5.0 (5.0e6.0)
Hypertension, n (%) 81 (58.3)
Diabetes, n (%) 31 (22.3)
Hyperlipidemia, n (%) 46 (33.1)
Hearth disease, n (%) 23 (16.5)
Smoking, n (%)
No 29 (20.9)
Former 82 (59.0)
Current 28 (20.1)
Alcohol, n (%)
Abstinent 84 (60.4)
Light 55 (39.6)
Previous penile surgery, n (%) 16 (11.5)
Duration of erectile dysfunction, n (%) 24.0 (12.0e48.0)
FSH (IU/L), median (IQR) 5.0 (1.9e8.0)
LH (IU/L), median (IQR) 5.6 (1.2e11)
TT (ng/mL), median (IQR) 7.7 (3e15)
TSH (mIU/L), median (IQR) 2.5 (0.8e5.2)
PRL (ng/mL), median (IQR) 6.6 (4e16)
BMI ¼ body mass index; ED ¼ erectile dysfunction; FSH ¼ follicle-
stimulating hormone; HADS ¼ Hospital Anxiety and Depression Scale;
IIEF ¼ International Index of Erectile Function; IQR ¼ interquartile range;
LH ¼ serum luteinizing hormone; MBI ¼ body max index; PRL ¼ prolactin;
TSH ¼ thyroid-stimulating hormone; TT ¼ total testosterone.
Figure 1. Study protocol. FCT ¼ film-coated tablet; ODF ¼ oro-
dispersible film.
1608 Cocci et alIn the study protocol (Figure 1), all patients were administered
sildenafil 100-mg FCT for 4 weeks. After a 2-week washout
period from sildenafil 100-mg FCT, all patients enrolled were
asked to take sildenafil 75-mg ODF alone (Rabestrom; IBSA).
They took the drug on demand, but they were asked to perform
sexual intercourse at least 2 times a week. For the FCT, patients
were told to take the tablet on an empty stomach 45 to 60
minutes before approaching the partner. For the ODF, patients
were instructed to put the film under the tongue or underneath
the palate, according to their preference.
Briefly, the preparation process of sildenafil 75-mg ODF ac-
cording to the WO 2014/049548 patent consists of the
following steps. Maltodextrin, a plasticizer (propylene glycol), the
active ingredient (sildenafil citrate), and the other excipients are
solubilized or dispersed in water; the mixture is coated onto a
release liner and dried in the oven at controlled temperature, air
circulation and coating speed; the dried mass is cut into reels; and
the films are punched, pouched, and sealed in suitable single-
dose sachets.
The impact of sildenafil on sexual function was evaluated by a
follow-up physician interview and patient self-administered
questionnaires. During the study protocol, the IEF-15 and the
Hospital Anxiety and Depression Scale (HADS) were adminis-
tered to all patients. The IIEF-15 scale classified the severity of
ED as severe (IIEF-15 score  10), moderate (IIEF-15 score ¼
11e16), or mild (IIEF-15 score ¼ 17e25).14 It covered the
domains of patients’ treatment response and satisfaction,partner’s treatment satisfaction, comparative previous treatment
satisfaction, adverse effects, and patient and partner quality of
life. The item on patient treatment response was rated on a scale
of 1 to 5, with scores of 4 and 5 indicating complete satisfactory
sexual intercourse on most occasions and almost always,
respectively. The IIEF-15 sub-scores were rated: erectile
function (IIEF-EF), orgasmic function (IIEF-OF), sexual desire
(IIEF-SD), intercourse satisfaction (IIEF-IS), and overall satis-
faction (IIEF-OS). The HADS was used to determine levels of
anxiety and depression that a patient was experiencing on a scale
of 0 to 21 as normal (0e7), borderline abnormal (8e10), or
abnormal (11e21). Patient Global Impression of Improvement
(PGI-I) and Clinician Global Impression of Improvement (CGI-I)
scales were completed to evaluate patient satisfaction after drug
administration. PGI-I estimated the score that best described theJ Sex Med 2017;14:1606e1611
Table 2. Mean changes of variables from baseline to washout and final follow-up
Variables From baseline to washout From washout to final follow-up Sildenafil 100-mg FCT vs 75-mg ODF
IEEF score, mean (SD)
Erectile function 10.46 (3.43)* 9.71 (3.60)* 0.74 (1.44)*
Orgasmic function 3.63 (2.42)* 3.07 (2.42)* 0.56 (1.12)*
Sexual desire 4.37 (2.12)* 4.06 (1.83)* 0.30 (1.51)†
Intercourse satisfaction 6.81 (3.48)* 5.12 (4.75)* 1.68 (3.90)*
Overall satisfaction 0.41 (0.91)* 1.12 (2.55)* 0.71 (2.65)*
Overall satisfaction 0.41 (0.91)* 1.12 (2.55)* 0.71 (2.65)*
HADS score, mean (SD) 1 (0.5)* 0.8 (0.55)* 0.1 (0.05)
FCT ¼ film-coated tablet; HADS ¼ Hospital Anxiety and Depression Scale; IIEF ¼ International Index of Erectile Function; ODF ¼ oro-dispersible film.
*P < .01; †P < .05.
Efficacy of a New Sildenafil Oral Formulation 1609postoperative condition, from 1 (very much better) to 7 (very
much worse). The CGI-I was used to evaluate the response to the
question, “Compared to his condition at baseline, how much has
he changed?” (1¼ very much improved to 7¼ very much worse).
Each patient signed a written fully informed consent state-
ment before being enrolled in the study. Institutional review
board approval was not necessary because the study concerned a
drug already widely known and used for ED, but only in a new
formulation.
Mouth time (seconds) was measured as the time from inges-
tion to final dissolution of the drug. Action time (minutes) was
measured as the time from ingestion to erection after sexual
stimulation.Figure 2. Changes of IIEF-15 from baseline to washout and final foll
International Index of Erectile Function erectile function domain; IIEF-I
domain; IIEF-OF ¼ International Index of Erectile Function orgasmic f
overall satisfaction domain; IIEF-SD ¼ International Index of Erectile F
J Sex Med 2017;14:1606e1611Data were analyzed using standard descriptive statistics, the
Student t-test, and linear regression with IBM SPSS 20.0 (IBM
Corp, Armonk, NY, USA).
RESULTS
139 patients completed the final protocol. The baseline
characteristics of patients at enrollment are presented in Table 1.
For patient history, 16 patients (11.5%) underwent previous
penile surgery, 5 of whom (3.6%) underwent a penile frenulo-
plasty, 9 (6.5%) underwent a circumcision for a tightened phi-
mosis, and 2 (1.4%) underwent surgical removal of penile
condyloma. At baseline, all hormonal parameters were in the
normal range in the 2 groups and were not related to theow-up (P < .005 by c2 test). FCT ¼ film-coated tablet; IIEF-EF ¼
S ¼ International Index of Erectile Function intercourse satisfaction
unction domain; IIEF-OS ¼ International Index of Erectile Function
unction sexual desire domain; ODF ¼ oro-dispersible film.
1610 Cocci et altreatment response. All patients presented normal ultrasound
duplex findings (blood flow > 30 cm/second, end-diastolic ve-
locity < 3 cm/second, resistance index > 0.8).
Table 2 presents mean changes of IIEF sub-scores from
baseline to washout to final follow-up. Specifically, all IIEF sub-
scores significantly decreased after the sildenafil washout period
and significantly increased after use of the ODF formulation. For
the comparison between sildenafil 100-mg FCT and sildenafil
75-mg ODF, we found significant differences in favor of sil-
denafil 100-mg FCT for IIEF-EF, IIEF-OF, IIEF-SD, and IIEF-
IS and differences in favor of sildenafil 75-mg ODF for IIEF-OS.
Figure 2 shows the absolute value of IIEF sub-scores during the
study protocol.
For change in HADS score, we did not find significant dif-
ferences from baseline to the sildenafil 100-mg FCT washout
(mean difference ¼ 0.0; P ¼ 1.0), whereas significant differences
were observed from the sildenafil 100-mg FCT washout to the
final follow-up (mean difference ¼ 0.19; P < .01).
For the ODF formulation, median CGI-I score was 3.5
(interquartile range [IQR] ¼ 2.5e4.5) and median PGI-I score
was 3.0 (IQR ¼ 2.0e4.0). Concerning the time of action of
sildenafil 75-mg ODF, median mouth time and action time were
60.0 seconds (IQR ¼ 30.0e120.0) and 20.0 minutes (IQR ¼
15.0e30.0), respectively. All patients completed the study.
There were 116 treatment-emergent adverse events (83.5%), all
related to the bad taste. For global impression, 119 patients
(85.6%) stated they would take the new drug again and 124
(89.2%) would suggest the drug to other patients.DISCUSSION
In recent decades, many drug-delivery systems, including
films, gels, chewing gums, and drug-loaded micro- and nano-
particles, have been developed as alternatives to conventional
dosage forms, with the aim of improving patient convenience,
acceptability, and compliance. Orally disintegrating films are
much more convenient than the “old” oral tablet, because they
are easily portable, do not need water to be taken, and can bypass
the swallowing issues that some patients might experience. In
fact, with this formulation, it would be sufficient to place it in
the mouth and await its complete dissolution. It also is conve-
nient for patients who have restrictions on daily fluid intake,
such as those with decreased kidney function, congestive heart
failure, and adrenal gland or endocrine system disorders. Ideally,
the perfect drug-carrying film should be non-irritating, non-
toxic, easily dissolved, and tasteless.
The median action time of sildenafil ODF in this study was 20
minutes; therefore, it has a greater rapidity of absorption, which
can be attributed to its pre-gastric absorption.
In this study, the sildenafil ODF, hydrated by saliva when
placed into the oral cavity, dissolved in approximately 1
minute. As expected, the only side effects recorded were related
to bad taste, possibly because all patients had been usingsildenafil 100-mg FCTs, which a priori excluded all patients
who had previously suspended PDE5i therapy because of other
side effects. Nevertheless, we can safely state that the new
formulation of sildenafil 75 mg does not add any side effects to
the “old” FCT formulation. Further studies in drug-naïve
patients should be conducted to address the extent and
frequency of side effects.
Furthermore, although more than 80% of patients expressed
their concerns about the taste of this new formulation when
dissolved in the mouth, almost 90% stated that they would
recommend the drug to other patients, which reflects the
excellent feedback reported. An important aspect that needs to
be evaluated is the psychological aspect of patients taking sil-
denafil in this new formulation. Specifically, the ODF formu-
lation could massively improve the quality of sexual life and
psychological well-being of patients with ED because of its
rapidity of action and ease of administration and because as it
does not require water, glasses, or other objects necessary to
take a tablet. This might explain why, despite the IIEF-EF,
IIEF-OF, IIEF-SD, and IIEF-IS domain scores in favor of
sildenafil 100-mg FCT, almost all patients stated they would
recommend this new formulation. If so, then andrologists
should approach ED treatments differently. The limitations of
the study are related to the methodology used, because this was
not a case-control study and the patients were not drug-naïve
to ED treatment. For this reason, this article reports only the
side effects related to the ODF but does not mention other side
effects. This is obviously due to the selection of our patients,
who were accustomed to treatment with sildenafil and might
not have reported the typical side effects of PDE5i. In the
future, a study on drug-naïve patients might provide a better
understanding of the side effects.
In the production process for this film, the drug is evenly
placed on the entire surface of the film.14 Thus, by geometrically
dividing this sheet of oral film exactly in the middle, one would
be certain that the patient is taking exactly half the dosage. This
might be useful in the common medical practice of advising the
patient to take only part of the dosage when the effects of the full
dosage are excessive.CONCLUSIONS
The new ODF formulation is efficient and safe and does not
add any side effect compared with the conventional FCT
formulation. The introduction of a new sildenafil ODF provides
a new option to the specialist for more precise tailored therapy.
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